Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients

doi:10.3969/j.issn.1006-7795.2015.04.007

Abstract

Abstract:

Objective The aim of this study was to investigate the potential clinical prognosis significance of progesterone receptor membrane component 1(PGRMC1) for breast cancer patients. Methods Fifty cases of breast cancer patients were derived from the Beijing Obstetrics and Gynecology hospital, Capital Medical University from Jan. 2008 to Dec 2014. Clinical and pathological data in details, such as date of primary diagnosis date, age, histologic grade, tumor size, lymph node metastasis, and patient follow-up information were collected and retrospectively analyzed. Immunohistochemical staining were carried out manually to evaluated the expression of estrogen receptor α(ERa)、progesterone receptor(PR)、Ki67 and PGRMC1 in breast cancer samples. Results For all the 50 tissues, the hormonal receptor status was 48.0% ERα positive(n=24), 42.0% PR positive(n=21), 4% Ki67 positive(n=2). Of the samples, 70.0%(n=35) were PGRMC1 positive. The result showed one statistically significant correlation, between PGRMC1 and tumor size, lymph node metastas(OR=1.60, 95%CI: 1.11-2.29; OR=1.12, 95%CI: 1.02-1.23). The association between conventional clinicopathological features and prognosis in breast cancer patients were evaluated. PGRMC1 expression would be used as predictors of recurrence(P=0.011) and poor overall survival(P=0.028) in breast cancer patients in Cox's proportional hazard model. Conclusion The high PGRMC1 level was associated with poor disease free survival rate and overall survival rate. PGRMC1 might be a independent prognostic factor breast cancer in the future.

Key words: breast cancer, progesterone receptor membrane component 1(PGRMC1), estrogen receptor, prognosis factor

CLC Number:

R737.9

Zhang Ying, Ruan Xiangyan, Mi Xin, Wang Gangyue, Alfred O. Mueck. Study of prognostic impact of progesterone receptor membrane component 1 (PGRMC1) in breast cancer patients[J]. Journal of Capital Medical University, 2015, 36(4): 548-552.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.04.007

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I4/548

References

[1] Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010[J]. Chin J Cancer Res, 2014,26(1):48-58.
[2] Cahill M A. Progesterone receptor membrane component 1: an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105(1-5):16-36.
[3] Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development[J]. Climacteric, 2013,16(5):509-513.
[4] Neubauer H, Seeger H, Ruan X. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J]. Menopause, 2011,18(8):845-850.
[5] Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferatiion of human breast cancer cells[J]. Climacteric, 2012,15(5):467-472.
[6] Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013,20(5):504-510.
[7] Neubauer H, Chen R, Schneck H, et al. Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J]. Horm Mol Biol Clin Investig, 2011,6(1):185-192.
[8] Crudden G, Chitti R E, Craven R J. Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J]. Pharmacol Exp Ther, 2006,316(1):448-455.
[9] Ahmed I S, Rohe H J, Twist K E, et al. Pgrmc1(progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity[J]. J Biol Chem, 2010,285(32):24775-24782.
[10] Peluso J J, Pappalardo A, Losel R, et al. Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability[J]. Biol Reprod, 2005,73(2):261-270.
[11] Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study[J]. J Clin Oncology, 2005,23(30):7512-7517.
[12] Haerslev T, Jacobsen G K, Zedeler K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen(PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas[J]. Breast Cancer Res Treatment, 1996,37:101-113.
[13] 张岳超,王雪梅,王丽萍.乳腺癌预后分子生物学标志物的研究进展[J].使用检验医师,2013,5(4):248-250.
[14] 崔玉洁,张凯,苏同义,等.乳腺癌分子靶向治疗研究进展[J].解放军医药杂志,2014,26(1):95-98.
[15] 李世超,姜军.乳腺癌循环肿瘤细胞生物学特性的研究进展[J].中华肿瘤防治杂志,2012,19(16):1272-1275.
[16] 徐兵河.乳腺癌的分子靶向治疗进展[J].中国医科大学学报,2013,42(12):1057-1060,1064.
[17] 曹丹霞,何建蓉,沈坤炜,等.激素受体和HER-2及Ki-67预测乳腺癌新辅助化疗疗效价值的分析[J].中华肿瘤防治杂志,2012,19(13):1000-1003.
[18] 王永南,王颀,张安秦,等.Ki-67与分子亚型预测乳腺癌新辅助化疗敏感性的研究[J].中华肿瘤防治杂志,2012,19(23):1805-1809.